Diabetes and Cardiovascular Disease: Evaluation, Prevention & Management presents the epidemiologic relation of diabetes and associated risk factors with cardiovascular disease. This concise guide demonstrates the role of non-invasive imaging strategies for evaluation of cardiovascular disease risk in diabetes, and the role of nutrition and physical activity in preventing diabetes and its cardiovascular complications. Diabetes and Cardiovascular Disease: Evaluation, Prevention & Management also covers the relation of chronic kidney disease to diabetes and cardiovascular consequences, and offers glycaemic control strategies for reducing the risk of cardiovascular disease with diabetes. The wide scope of this book makes it an essential resource for diabetologists, cardiologists and physicians. Key Features Presents the relationship between diabetes and cardiovascular disease Focus on prevention and management, including chapter on quality of care and provider/medical systems in diabetes management Edited by team of experts in the field from the University of California

Diabetes and Cardiovascular Disease: Evaluation, Prevention & Management presents the epidemiologic relation of diabetes and associated risk factors with cardiovascular disease. This concise guide demonstrates the role of non-invasive imaging strategies for evaluation of cardiovascular disease risk in diabetes, and the role of nutrition and physical activity in preventing diabetes and its cardiovascular complications.

Cardiovascular Diseases (CVDs) are the number one cause of death and disability globally, being the most important public health problem that needs to be tackled as more people die annually from CVDs than from any other cause. Over three-quarters of CVD deaths take place in low- and middle-income countries. This book on cardiovascular diseases provides an overview of the global and regional challenges associated with CVDs. Coupled with case studies and theoretical concepts, it helps the reader to contextualize CVDs in the broader public health system and the administrative aspects of practicing CVD control approaches for improved population health in their local setting. Key Features:1. Covers existing and emerging issues in cardiovascular disease epidemiology and prevention. 2. Has a multidisciplinary approach in content and audience. 3. Connects with health systems and relevant sustainable development goals. 4. Provides case studies for enabling readers to understand and apply evidence-based solutions to key public health issues. 5. Has inputs from globally renowned public health experts.

Diabetes and hypertension have evolved as two of the modern day epidemics affecting millions of people around the world. These two common co-morbidities lead to substantial increase in cardiovascular disease, the major cause of morbidity and mortality of adults around the world. In Diabetes and Hypertension: Evaluation and Management, a panel of renowned experts address a range of critical topics -- from basic concepts in evaluation and management of diabetes and hypertension, such as dietary interventions, to evaluation and management of secondary hypertension in clinical practice. Other chapters focus on high cardiovascular risk populations such as those with coronary heart disease, chronic kidney disease and minority patients. In addition, evolving concepts and new developments in the field are presented in other chapters, such as prevention of type 2 diabetes and the epidemic of sleep apnea and its implication for diabetes and hypertension evaluation and management. An important title covering two of the most troubling disorders of our time, Diabetes and Hypertension: Evaluation and Management will provide the busy practitioner with cutting edge knowledge in the field as well as practical information that can translate into better care provided to the high-risk population of diabetics and hypertensive patients.

This title will be presented as highly practical information pn pharmaceutical antiplatelet and anticoagulation therapy, written in a quick-access, no-nonsense format. The emphasis will be on a just-the-facts clinical approach, heavy on tabular material, light on dense prose. The involvement of the ISCP will ensure that the best quality contributors will be involved and establish a consistent approach to each topic in the series. Each volume is designed to be between 120 and 250 pages containing practical illustrations and designed to improve understand and practical usage of cardiovascular drugs in specific clinical areas.

Cardiovascular, respiratory, and related conditions cause more than 40 percent of all deaths globally, and their substantial burden is rising, particularly in low- and middle-income countries (LMICs). Their burden extends well beyond health effects to include significant economic and societal consequences. Most of these conditions are related, share risk factors, and have common control measures at the clinical, population, and policy levels. Lives can be extended and improved when these diseases are prevented, detected, and managed. This volume summarizes current knowledge and presents evidence-based interventions that are effective, cost-effective, and scalable in LMICs.

Practical ABC style Enables doctors to prioritise treatment using risk-scoring systems and holistic recommendations for reducing cardiovascular risk Includes treatment plans for individuals with diabetes, who are at high risk of developing cardiovascular disease How to reduce cardiovascular risk in other specific patient groups Developed by expert groups in different regions of the world

With cardiovascular disease becoming the most common cause of death in people with diabetes, interest in the assessment and treatment of heart disease in these patients has been reawakened. This book examines developing topics from a largely cardiological perspective, covering both pharmacological and non-pharmacological interventions. The DIGAMI study on the use of intravenous insulin infusion at the time of myocardial infarction (MI) has stimulated a large number of discussion papers on the best treatment of MI in the diabetic patient. The UKPDS has shown that treatment of Type 2 diabetes does not reduce cardiovascular end-points significantly, but that aggressive treatment of blood pressure can do so. In addition, sub-group analysis from several large cardiovascular trials has shown that treatment with statins, anti-platelet therapy, ACE inhibitors and other drugs will also reduce cardiovascular events in people with diabetes.